Annual Current Liabilities:
$195.49M+$92.32M(+89.48%)Summary
- As of today, ARWR annual current liabilities is $195.49 million, with the most recent change of +$92.32 million (+89.48%) on September 30, 2025.
- During the last 3 years, ARWR annual current liabilities has risen by +$56.64 million (+40.79%).
- ARWR annual current liabilities is now at all-time high.
Performance
ARWR Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Current Liabilities:
$195.49M+$957.00K(+0.49%)Summary
- As of today, ARWR quarterly current liabilities is $195.49 million, with the most recent change of +$957.00 thousand (+0.49%) on September 1, 2025.
- Over the past year, ARWR quarterly current liabilities has increased by +$92.32 million (+89.48%).
- ARWR quarterly current liabilities is now -11.36% below its all-time high of $220.54 million, reached on March 31, 2025.
Performance
ARWR Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
ARWR Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +89.5% | +89.5% |
| 3Y3 Years | +40.8% | +40.8% |
| 5Y5 Years | +380.5% | +380.5% |
ARWR Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +89.5% | -11.4% | +206.8% |
| 5Y | 5-Year | at high | +380.5% | -11.4% | +679.0% |
| All-Time | All-Time | at high | >+9999.0% | -11.4% | >+9999.0% |
ARWR Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | $195.49M(+89.5%) | - |
| Sep 2025 | - | $195.49M(+0.5%) |
| Jun 2025 | - | $194.53M(-11.8%) |
| Mar 2025 | - | $220.54M(+135.2%) |
| Dec 2024 | - | $93.76M(-9.1%) |
| Sep 2024 | $103.17M(-2.2%) | $103.17M(+6.7%) |
| Jun 2024 | - | $96.71M(+48.4%) |
| Mar 2024 | - | $65.17M(+2.3%) |
| Dec 2023 | - | $63.72M(-39.6%) |
| Sep 2023 | $105.46M(-24.1%) | $105.46M(+50.2%) |
| Jun 2023 | - | $70.23M(-19.4%) |
| Mar 2023 | - | $87.15M(-28.6%) |
| Dec 2022 | - | $122.01M(-12.1%) |
| Sep 2022 | $138.85M(-5.2%) | $138.85M(+8.3%) |
| Jun 2022 | - | $128.21M(-7.7%) |
| Mar 2022 | - | $138.86M(+1.3%) |
| Dec 2021 | - | $137.03M(-6.5%) |
| Sep 2021 | $146.54M(+260.2%) | $146.54M(-25.0%) |
| Jun 2021 | - | $195.43M(+16.9%) |
| Mar 2021 | - | $167.19M(+566.2%) |
| Dec 2020 | - | $25.09M(-38.3%) |
| Sep 2020 | $40.68M(-58.1%) | $40.68M(-4.9%) |
| Jun 2020 | - | $42.78M(-19.8%) |
| Mar 2020 | - | $53.33M(-27.6%) |
| Dec 2019 | - | $73.70M(-24.1%) |
| Sep 2019 | $97.07M(+685.0%) | $97.07M(+11.5%) |
| Jun 2019 | - | $87.09M(-14.5%) |
| Mar 2019 | - | $101.81M(-24.4%) |
| Dec 2018 | - | $134.61M(+988.7%) |
| Sep 2018 | $12.37M(-33.9%) | $12.37M(+73.5%) |
| Jun 2018 | - | $7.13M(-21.9%) |
| Mar 2018 | - | $9.12M(-33.5%) |
| Dec 2017 | - | $13.72M(-26.7%) |
| Sep 2017 | $18.70M(-27.1%) | $18.70M(-8.0%) |
| Jun 2017 | - | $20.32M(-26.2%) |
| Mar 2017 | - | $27.55M(-25.5%) |
| Dec 2016 | - | $37.00M(+44.3%) |
| Sep 2016 | $25.64M(+61.3%) | $25.64M(+72.8%) |
| Jun 2016 | - | $14.84M(+5.6%) |
| Mar 2016 | - | $14.06M(+14.0%) |
| Dec 2015 | - | $12.33M(-22.5%) |
| Sep 2015 | $15.90M(+34.2%) | $15.90M(+66.8%) |
| Jun 2015 | - | $9.53M(-27.8%) |
| Mar 2015 | - | $13.21M(+14.9%) |
| Dec 2014 | - | $11.50M(-2.9%) |
| Sep 2014 | $11.85M(+35.8%) | $11.85M(+43.6%) |
| Jun 2014 | - | $8.25M(-21.3%) |
| Mar 2014 | - | $10.48M(+16.2%) |
| Dec 2013 | - | $9.02M(+3.4%) |
| Sep 2013 | $8.72M(+63.8%) | $8.72M(+30.7%) |
| Jun 2013 | - | $6.68M(-6.8%) |
| Mar 2013 | - | $7.16M(+17.9%) |
| Dec 2012 | - | $6.08M(+14.1%) |
| Sep 2012 | $5.33M | $5.33M(-8.4%) |
| Jun 2012 | - | $5.82M(-8.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $6.38M(+26.0%) |
| Dec 2011 | - | $5.06M(+96.0%) |
| Sep 2011 | $2.58M(-39.6%) | $2.58M(+19.5%) |
| Jun 2011 | - | $2.16M(-13.4%) |
| Mar 2011 | - | $2.49M(-68.4%) |
| Dec 2010 | - | $7.90M(+84.8%) |
| Sep 2010 | $4.28M(+82.4%) | $4.28M(-16.8%) |
| Jun 2010 | - | $5.14M(+125.5%) |
| Mar 2010 | - | $2.28M(-11.6%) |
| Dec 2009 | - | $2.58M(+10.1%) |
| Sep 2009 | $2.34M(-37.1%) | $2.34M(-31.3%) |
| Jun 2009 | - | $3.41M(-23.4%) |
| Mar 2009 | - | $4.45M(-8.5%) |
| Dec 2008 | - | $4.86M(+30.4%) |
| Sep 2008 | $3.73M(+28.7%) | $3.73M(+45.8%) |
| Jun 2008 | - | $2.56M(+11.4%) |
| Mar 2008 | - | $2.29M(+0.4%) |
| Dec 2007 | - | $2.28M(-21.2%) |
| Sep 2007 | $2.90M(-0.8%) | $2.90M(-1.5%) |
| Jun 2007 | - | $2.94M(+156.5%) |
| Mar 2007 | - | $1.15M(+12.9%) |
| Dec 2006 | - | $1.02M(-65.2%) |
| Sep 2006 | $2.92M(+185.1%) | $2.92M(+68.9%) |
| Jun 2006 | - | $1.73M(-33.2%) |
| Mar 2006 | - | $2.59M(+77.8%) |
| Dec 2005 | - | $1.46M(+42.2%) |
| Sep 2005 | $1.02M(+48.5%) | $1.02M(+3.2%) |
| Jun 2005 | - | $992.70K(+71.4%) |
| Mar 2005 | - | $579.20K(+64.6%) |
| Dec 2004 | - | $351.90K(-49.0%) |
| Sep 2004 | $689.70K(+616.9%) | $689.70K(+84.9%) |
| Jun 2004 | - | $373.00K(+871.4%) |
| Mar 2004 | - | $38.40K(+89.2%) |
| Dec 2003 | - | $20.30K(-78.9%) |
| Sep 2003 | $96.20K(-93.9%) | $96.20K(-94.6%) |
| Jun 2003 | - | $1.77M(+3.3%) |
| Mar 2003 | - | $1.72M(+6.1%) |
| Dec 2002 | - | $1.62M(+1.9%) |
| Sep 2002 | $1.59M(+20.4%) | $1.59M(+2.9%) |
| Jun 2002 | - | $1.54M(+10.3%) |
| Mar 2002 | - | $1.40M(+1.0%) |
| Dec 2001 | - | $1.38M(+5.0%) |
| Sep 2001 | $1.32M(+14.1%) | $1.32M(+4.0%) |
| Jun 2001 | - | $1.27M(+2.7%) |
| Mar 2001 | - | $1.23M(+4.2%) |
| Dec 2000 | - | $1.18M(+2.5%) |
| Sep 2000 | $1.16M(+11.6%) | $1.16M(-2.9%) |
| Jun 2000 | - | $1.19M(+4.7%) |
| Mar 2000 | - | $1.14M(+4.8%) |
| Dec 1999 | - | $1.08M(+4.8%) |
| Sep 1999 | $1.04M(-61.2%) | $1.04M(+6.1%) |
| Jun 1999 | - | $976.10K(-62.6%) |
| Mar 1999 | - | $2.61M |
| Sep 1998 | $2.67M(-0.6%) | - |
| Sep 1997 | $2.68M | - |
FAQ
- What is Arrowhead Pharmaceuticals, Inc. annual current liabilities?
- What is the all-time high annual current liabilities for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. annual current liabilities year-on-year change?
- What is Arrowhead Pharmaceuticals, Inc. quarterly current liabilities?
- What is the all-time high quarterly current liabilities for Arrowhead Pharmaceuticals, Inc.?
- What is Arrowhead Pharmaceuticals, Inc. quarterly current liabilities year-on-year change?
What is Arrowhead Pharmaceuticals, Inc. annual current liabilities?
The current annual current liabilities of ARWR is $195.49M
What is the all-time high annual current liabilities for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high annual current liabilities is $195.49M
What is Arrowhead Pharmaceuticals, Inc. annual current liabilities year-on-year change?
Over the past year, ARWR annual current liabilities has changed by +$92.32M (+89.48%)
What is Arrowhead Pharmaceuticals, Inc. quarterly current liabilities?
The current quarterly current liabilities of ARWR is $195.49M
What is the all-time high quarterly current liabilities for Arrowhead Pharmaceuticals, Inc.?
Arrowhead Pharmaceuticals, Inc. all-time high quarterly current liabilities is $220.54M
What is Arrowhead Pharmaceuticals, Inc. quarterly current liabilities year-on-year change?
Over the past year, ARWR quarterly current liabilities has changed by +$92.32M (+89.48%)